NCT00088543 - Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

Acute Myelogenous Leukemia (AML)Acute Lymphocytic Leukemia (ALL)Graft vs. Host Disease (GvHD)

Interventions

BIOLOGICAL

Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]

total dose 4.5 mg/kg

BIOLOGICAL

Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]

total dose 8.5 mg/kg

Trial Locations (14)

19104

University of Pennsylvania, Philadelphia

27705

Duke University Medical Center, Durham

30322

Emory University Hospital, Atlanta

32610

Shands at the University of Florida, Division of Hematology/Oncology, Gainesville

35249

University of Alabama-Birmingham Hospital, Birmingham

63110

Washington University School of Medicine, St Louis

68198

The Nebraska Medical Center, Omaha

90095

UCLA Medical Center, Los Angeles

02114

Massachusetts General Hospital Cox Bldg Room 640, Boston

02115

Dana Farber Cancer Institute Dana 1B11, Boston

02215

Beth Israel Deaconess Medical Center KS121, Brookline

07601

Cancer Center at Hackensack University Medical Center, Hackensack

K1H 8L6

Ottawa Hospital - General Campus, Ottawa

M5G 2M9

Princess Margaret Hospital, University Health Network, Toronto

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY